# A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals

> **NCT02766816** · PHASE3 · COMPLETED · sponsor: **Bilthoven Biologicals** · enrollment: 1120 (actual)

## Conditions studied

- Immune Response to Oral Polio Vaccine

## Interventions

- **BIOLOGICAL:** Part 1 study - BBio bOPV
- **BIOLOGICAL:** Part 2 study - BBio bOPV Lot 1
- **BIOLOGICAL:** Part 2 study - BBio bOPV Lot 2
- **BIOLOGICAL:** Part 2 study - BBio bOPV Lot 3
- **BIOLOGICAL:** Part 2 study - Licensed bOPV
- **BIOLOGICAL:** Part 1 study - Licensed bOPV

## Key facts

- **NCT ID:** NCT02766816
- **Lead sponsor:** Bilthoven Biologicals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-08
- **Primary completion:** 2018-02-14
- **Final completion:** 2018-02-14
- **Target enrollment:** 1120 (ACTUAL)
- **Last updated:** 2019-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02766816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02766816, "A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02766816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*